Summary by Moomoo AI
On February 6, 2024, Femasys Inc., a biomedical company specializing in women's health solutions, announced the appointment of Richard Spector as the new Chief Commercial Officer (CCO). Spector, with 25 years of experience in the healthcare sector, will spearhead the commercial launch of FemaSeed, an FDA-cleared infertility treatment, and FemBloc, a non-surgical permanent birth control product currently in late-stage clinical development. His previous roles include leadership positions at Qlibrium, Insulet Corporation, and OvaScience, Inc., among others. In conjunction with his appointment, Femasys granted Spector an inducement option to purchase 100,000 shares of common stock, vesting over four years, subject to continued employment. The company's portfolio includes the recently FDA-cleared FemaSeed, the late-clinical stage FemBloc, and other diagnostic products ready for commercialization.